Author: admintay

We’re excited to announce that Tay Therapeutics has secured intellectual property (IP) rights for our Topical BET Project from University of Dundee. This strategic milestone strengthens our control over BET inhibitor assets and enhances our flexibility for future licensing and partnerships.

This development further reinforces our readiness to transact on the BET asset portfolio, including VYN201 and VYN202, which were licensed to Vyne Therapeutics (NASDAQ: VYNE). By consolidating ownership, we are in a stronger position to maximize asset value and advance our broader drug discovery efforts.

“Securing this IP assignment is a key step in ensuring we retain strategic optionality around the VYN201 program,” said Andrew Woodland, CEO of Tay Therapeutics. “With growing evidence of the transformative potential of targeted BET inhibitors, we are now well-positioned for future partnerships or transactions.”

Expanding Tay Therapeutics as a Drug Discovery Engine

Beyond BET inhibitors, we continue to develop a pipeline of high-potential drug discovery programs, reinforcing Tay’s role as a biotech incubator. Our latest projects include:

🔹 Undisclosed Program: A first-in-class, oral, muscle-sparing anti-obesity therapy with addressing a key gap in the obesity market.

🔹 Read-through Program: A breakthrough oral, small molecule, gene therapy, progressing towards clinical readiness for severe genetic diseases like RDEB.

“Tay is a hub of innovation with the clinical progress of VYN201 and VYN202 highlighting the quality of our assets,” added Tim Sparey, Executive Chair. “With our BET IP secured and new projects gaining traction, we’re expanding discussions with investors and commercial partners.”

💡 See our journey in action — watch our latest video on LinkedIn

September 27, 2024

Dundee, Scotland, September 27, 2024 – Tay Therapeutics (“Tay”) today announced the publication of a composition of matter patent, WO2024194607, entitled “Pyrimido [4,5-B][1,5]naphthyridine-4,5(3H,10H)-dione derivatives for the treatment of diseases associated with PTC mutations, such as e.g. Cancer”, with the United Kingdom Intellectual Property Office (IPO) under the Patent Cooperation Treaty (PCT).

This new patent covers a proprietary class of Readthrough agents developed by Tay Therapeutics to address high-value opportunities in genetic diseases and certain cancers, including recessive dystrophic epidermolysis bullosa (RDEB). This intellectual property milestone reinforces Tay’s strategy to expand its therapeutic pipeline and enhance market opportunities through strategic partnerships and potential licensing deals.

“The publication of this patent strengthens Tay’s intellectual property portfolio and highlights our commitment to developing therapies for unmet needs,” said Andrew Woodland, CEO, Tay Therapeutics. “We are excited about the potential of our first-in-class Readthrough agents to transform treatment paradigms for severe genetic diseases and selected cancers.” This patent not only expands Tay’s intellectual property estate but also strengthens our positioning for future collaborations and commercial transactions in the biotech sector.”

For more information and partnership opportunities, get in touch with us.

 

 

 

BRIDGEWATER, N.J., June 13, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first healthy volunteers have been dosed in the Phase 1a trial of VYN202. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases. Top-line data are expected in the second half of 2024.

“We are pleased to announce the initiation of the first-in-human clinical trial of VYN202, a highly selective and potent orally administered BET inhibitor. In preclinical testing, VYN202 achieved consistent improvements in disease severity across a variety of inflammatory and fibrotic models as well as reductions in pro-inflammatory and disease-related biomarkers,” said David Domzalski, President and CEO of VYNE. “We believe VYN202 has significant potential as a treatment option for a broad range of immune-mediated diseases, and we look forward to reporting top-line data from the Phase 1a trial in the second half of this year.”

The Phase 1a trial is a first-in-human double-blind, placebo-controlled study in healthy volunteers and consists of single ascending dose (SAD) and multiple ascending dose (MAD) components. The trial is currently expected to enroll approximately 64 healthy adult subjects into five SAD and three MAD cohorts to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202.

“Early generation BET inhibitors show similar affinity to both BD1 and BD2 bromodomains of BET proteins that has been implicated in both gastrointestinal and hematologic dose limiting toxicities,” said Dr. Iain Stuart, Chief Scientific Officer of VYNE. “We believe VYN202’s high potency and selectivity towards the BD2 bromodomain of BET proteins may result in an improved benefit-risk profile when treating immuno-inflammatory diseases. Following highly encouraging preclinical data, we are eager to evaluate the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 to further inform our future clinical development plans.”

BRIDGEWATER, N.J., June 05, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first subject has been dosed in a Phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration. Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025.

The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. A total of approximately 160 subjects will be randomized at a 1:1:1:1 ratio. Following the 24-week treatment period, subjects in the active treatment arms will continue for an additional 28 weeks, and subjects in the vehicle group will be equally re-randomized to receive VYN201 1%, 2% or 3% gel for an additional 28 weeks. The primary efficacy endpoint of the trial is the proportion of subjects achieving an improvement in Facial Vitiligo Area Scoring Index of at least 50% from baseline (F-VASI50) at week 24 compared to vehicle, with additional secondary endpoints of F-VASI and Total VASI (T-VASI) at weeks 24 and 52.

“Dosing the first subject in the Phase 2b trial for vitiligo is an important milestone for the VYN201 program and our Company,” said David Domzalski, President and CEO of VYNE. “In our prior Phase 1b trial, VYN201 demonstrated a significant clinical response with a rapid onset of action and a favorable safety and tolerability profile, including low systemic exposure. We believe that VYN201 has the potential to become a valuable and differentiated therapy for patients with vitiligo. We look forward to reporting top-line data from the 24-week treatment period in mid-2025.”

October 1, 2023

Dundee, Scotland, October 1, 2023 – Tay Therapeutics (“Tay”) today announced it has been awarded a £0.35 million grant from Innovate UK, supporting the development of its pioneering Readthrough compounds through in vitro and in vivo proof-of-concept studies. The grant funding will accelerate preclinical research aimed at transforming treatments for genetic diseases caused by premature stop codons.

Andrew Woodland, CEO and Co-founder of Tay Therapeutics, commented: “Many diseases are driven by premature stop codons. This grant will allow us to explore the ability of our Readthrough drugs to overcome such premature stop codons, restoring normal protein levels and cellular function”. 

This strategic grant from Innovate UK enhances Tay’s ability to advance its Readthrough platform, positioning the company for future partnerships, licensing opportunities, and clinical development milestones. By demonstrating proof of concept, Tay Therapeutics aims to attract further investment and expand its therapeutic pipeline in high-value markets.